

Dengue Treatment Market, 2012-2023

<https://marketpublishers.com/r/D62879D9BA6EN.html>

Date: January 2018

Pages: 210

Price: US\$ 4,400.00 (Single User License)

ID: D62879D9BA6EN

Abstracts

Market Introduction: Dengue Treatment Market

Dengue fever is also known as break bone fever is mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several species of mosquitos of the Aedes type, principally A. aegypti. Symptoms of dengue include fever, headache vomiting, muscle and joint pains, and characteristic skin rash. On infection of dengue, patient will automatically recover within seven days. But in some cases, it may develop to life threatening dengue hemorrhagic fever. The virus has five different types of strains, infection with one strain usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications.

Market Dynamics: Dengue Treatment Market

Global dengue treatment market anticipated surging its growth owing to rise in dengue burden in tropical and sub-tropical regions, increased government funding to fight against dengue, and unmet market needs of managing dengue burden around the world. In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. However, lack or insufficient healthcare infrastructure in underdeveloped and developing regions leading to serious medical conditions going unnoticed. Furthermore, lack of awareness related to symptoms and the high-cost of treatment are hindering the dengue-treatment market.

Market Segmentation: Dengue Treatment Market

Dengue Treatment Market has been segmented on the basis of drug class and distribution channel

Based on drug class, dengue Treatment market is segmented into

NSAIDS

Antibiotics

Corticosteroids

Based on distribution channel, dengue Treatment market is segmented into

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Market overview: Dengue Treatment Market

Dengue Treatment market is expected to grow at a significant rate during forecast period. According to World Health Organization (WHO) estimates, 50 to 100 Mn infections occur annually, including 500,000 DHF cases and 22,000 deaths, mostly among children. Dengue treatment market is at developing stage. Market players collaborating to other companies or research institutions for the development of drugs for treating the dengue. For instance, in August 2013, Johnson and Johnson Services Inc. collaborated with biotechnology nonprofit organization The Wellcome Trust, for the development of prevention and treatment therapies for dengue fever.

Regional Overview: Dengue Treatment Market

Geographically Dengue Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Latin America market expected to grow owing to increased dengue cases. According to WHO, in 2010, 1.6 million cases of dengue were reported in the Americas alone. In Asia-Pacific region, dengue treatment market expected to grow at a high rate due to increase

in dengue coupled with an increase in government funding for dengue prevention and treatment. Market players in Asia are actively participating in development of dengue treating drugs to increase their market share. For instance, in May 2016, Sun Pharma collaborated with International Centre of Genetic Engineering and Biotechnology (ICGEB) to develop drug for treatment of dengue. South East Asia and Western Pacific regions are more seriously affected by dengue. Hence, companies are planning to launch their vaccines in South East Asia regions.

Market Participants: Dengue Treatment Market

Some of the market players in Dengue treatment market include F. Hoffmann-La Roche AG (Switzerland), Sun Pharmaceutical Industries Limited (India), Abbivax (France), Takeda Pharmaceutical Company Ltd (Japan), Merck & Co Inc. (U.S.), and VABIOTECH (Vietnam) to name a few.

Key Market Developments: Dengue Treatment Market

In September 2017, Abbivax and Evotec AG entered into strategic partnership to develop novel antiviral agents including dengue virus, influenza and others.

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL DENGUE TREATMENT MARKET INTRODUCTION

2.1. Global Dengue Treatment Market – Taxonomy

2.2. Global Dengue Treatment Market –Definitions

2.2.1. Drug Class

2.2.2. Distribution Channel

3. GLOBAL DENGUE TREATMENT MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Dengue Treatment Market Dynamic Factors - Impact Analysis

4. GLOBAL DENGUE TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL DENGUE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. NSAIDS

5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Antibiotics

5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Corticosteroids

5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

6. GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Oral

6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Parenteral

6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Others

6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

7. GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

8. GLOBAL DENGUE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. North America

- 8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis
- 8.2. Europe
 - 8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 8.2.3. Market Opportunity Analysis
- 8.3. Asia-Pacific
 - 8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 8.3.3. Market Opportunity Analysis
- 8.4. Latin America
 - 8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 8.4.3. Market Opportunity Analysis
- 8.5. Middle East and Africa
 - 8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 8.5.3. Market Opportunity Analysis
- 8.6. Global Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

- 9.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 9.1.1. NSAIDS
 - 9.1.2. Antibiotics
 - 9.1.3. Corticosteroids
- 9.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 9.2.1. Oral
 - 9.2.2. Parenteral
 - 9.2.3. Others
- 9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 9.3.1. Hospital Pharmacies
 - 9.3.2. Retail pharmacies

9.3.3. Online Pharmacies

9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

9.6. North America Dengue Treatment Market Dynamics – Trends

10. EUROPE DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. NSAIDS

10.1.2. Antibiotics

10.1.3. Corticosteroids

10.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.2.1. Oral

10.2.2. Parenteral

10.2.3. Others

10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.3.1. Hospital Pharmacies

10.3.2. Retail pharmacies

10.3.3. Online Pharmacies

10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

10.6. Europe Dengue Treatment Market Dynamics – Trends

11. ASIA-PACIFIC DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. NSAIDS

11.1.2. Antibiotics

11.1.3. Corticosteroids

11.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Oral

11.2.2. Parenteral

11.2.3. Others

11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.3.1. Hospital Pharmacies

11.3.2. Retail pharmacies

11.3.3. Online Pharmacies

11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

11.6. Asia-Pacific Dengue Treatment Market Dynamics – Trends

12. LATIN AMERICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. NSAIDS

12.1.2. Antibiotics

12.1.3. Corticosteroids

12.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Oral

12.2.2. Parenteral

12.2.3. Others

12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.3.1. Hospital Pharmacies

12.3.2. Retail pharmacies

12.3.3. Online Pharmacies

12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

12.6. Latin America Dengue Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

13.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. NSAIDS

13.1.2. Antibiotics

13.1.3. Corticosteroids

13.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.2.1. Oral

13.2.2. Parenteral

13.2.3. Others

13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.3.1. Hospital Pharmacies

13.3.2. Retail pharmacies

13.3.3. Online Pharmacies

13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

13.5. MEA Dengue Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023

13.6. MEA Dengue Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. F. Hoffmann-La Roche AG (Switzerland)

14.2.2. Sun Pharmaceutical Industries Limited (India)

14.2.3. Abbivax (France)

14.2.4. Takeda Pharmaceutical Company Ltd (Japan)

14.2.5. Merck & Co Inc. (U.S.)

14.2.6. VABIOTECH (Vietnam)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Dengue Treatment Market, 2012-2023

Product link: <https://marketpublishers.com/r/D62879D9BA6EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D62879D9BA6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970